Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2017-06-06 Declaration of Voting R…
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document announces two main pieces of news: reaching 1,000 echotherapy treatments and detailing 'Changes in the distribution of Theraclion's capital' by comparing shareholding percentages between August 2016 and May 2017, specifically noting a threshold crossing by Truffle Capital. The detailed tables showing ownership percentages and theoretical voting rights directly relate to significant changes in share ownership, which aligns with the definition of Major Shareholding Notification (MRQ). While it mentions the AGM section on the website, the core content is the capital structure update and major shareholder movement, not the AGM materials themselves or a general regulatory filing.
2017-06-06 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Major Shareholding Notification Classification · 95% confidence The document is a press release dated June 6, 2017, announcing two key updates: reaching 1000 echotherapy treatments and detailing changes in the company's capital structure (shareholder voting rights). The capital structure update specifically mentions a shareholder (Truffle Capital) crossing a threshold (50% voting rights threshold crossed downwards) and provides detailed tables comparing shareholding percentages as of May 11, 2017, and August 20, 2016. This type of announcement, focusing on significant changes in share ownership and voting rights, directly aligns with the definition of Major Shareholding Notification (MRQ). While it also mentions AGM information at the end, the core substance is the change in ownership structure.
2017-06-06 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated May 23, 2017, announcing the publication of three clinical studies regarding Theraclion's Echopulse device for treating thyroid nodules. It details the findings of these studies, quotes management, and provides company background and contact information. This type of announcement, focusing on clinical validation and scientific publications, does not fit neatly into the standard financial filing categories (10-K, ER, IR, etc.). It is a general corporate announcement related to product validation and scientific progress, which is best categorized as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as a deck, but given the format, RNS serves as the most appropriate general regulatory/corporate news category for non-standard announcements.
2017-05-23 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated May 23, 2017, announcing the publication of three scientific articles supporting the use of their Echopulse® technology for treating thyroid nodules. It details the findings of these studies, including comparisons to surgery, and includes quotes from management about accelerating clinical adoption. This format—a news announcement about clinical/scientific developments and their impact on the business—is characteristic of a general press release or regulatory announcement. Since it is not a formal financial report (10-K, IR, ER, MRQ) nor a specific management/board change, dividend notice, or proxy material, it falls best under the general 'Regulatory Filings' (RNS) category, which often captures press releases detailing significant operational or scientific milestones that may be required for regulatory disclosure, or it could be considered an Investor Relations document. Given the options, RNS serves as the best general regulatory/news announcement fallback. It is not an Earnings Release (ER) as it focuses on clinical data, not period financial results.
2017-05-23 French
Communications during bidding periods / Other releases
AGM Information Classification · 99% confidence The document explicitly announces the 'outcome of its combined ordinary and extraordinary shareholders' general meeting' held on May 11, 2017. It details the resolutions passed, including the approval of 2016 financial statements and the ratification of a new director. This content directly relates to the proceedings and results of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document is a summary announcement of the meeting results, not a proxy statement (PSI) or a declaration of voting results (DVA), but rather the official report/summary of the meeting itself.
2017-05-12 English
Communiqués en période d’offre / Autres communiqués
AGM Information Classification · 99% confidence The document is titled 'Assemblée générale ordinaire et extraordinaire annuelle de Theraclion' (Annual Ordinary and Extraordinary General Meeting of Theraclion) and explicitly states that 'Toutes les résolutions agréées par le conseil d'administration ont été adoptées par les actionnaires' (All resolutions approved by the board of directors were adopted by the shareholders). It details the results of the general meeting held on May 11, 2017, including the ratification of a director's co-option and approvals for financial authorizations. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2017-05-12 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.